EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BelloStage™-3000 Bioreactor Versus Conventional Cultivation of Recombinant Capripoxvirus Expressing Brucella Antigens in Vero Cells: A Step Towards the Development of a New Human Brucellosis Vaccine

Zhanat Amanova, Zhanna Sametova iD, Olga Chervyakova iD, Sholpan Turyskeldi iD, Alina Kurmasheva iD, Ruslan Abitayev iD, Abdurakhman Ussembay iD, Zhanat Kondibayeva iD, Dariya Toktyrova iD, Dana Mazbayeva iD, Yerbol Bulatov iD

Cells · 20.10.2025 · 14 (20) · 1631

DOI: 10.3390/cells14201631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 20.10.2025. Verfasst von Zhanat Amanova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Biological Safety Problems, National Holding "QazBioPharm", Gvardeiskiy 080409, Kazakhstan. Hauptthemen laut MEDLINE: Bioreactors, Capripoxvirus, Antigens, Bacterial, Brucella. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Republic of Kazakhstan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brucellosis remains one of the most significant zoonotic diseases, posing a serious threat to both human health and livestock. This issue is particularly relevant for Kazakhstan, which is among the countries endemic for brucellosis with a high incidence rate. Such circumstances highlight the urgent need for the development and implementation of effective preventive measures, including modern vaccine platforms capable of providing reliable protection for the population and reducing the economic impact on the agricultural sector. Recombinant capripoxviruses are considered promising vector platforms for vaccine development, as they ensure high expression of target antigens, elicit strong immune responses, and are safe for humans. In this study, the replication of recombinant capripoxviruses expressing Brucella antigens (SPPV (TK-) OMP19/SODC and SPPV (TK-) OMP25) was evaluated in Vero cells using the BelloStage™-3000 bioreactor system in combination with BioNOC II® macrocarriers. Application of the bioreactor resulted in nearly a 100-fold increase in Vero cell density compared with static cultures and provided optimal conditions for cell adhesion, growth, and metabolic activity. Consequently, a significant increase in viral titers was observed: for SPPV (TK-) OMP19/SODC, mean titers reached 7.50 log10 TCID50/mL versus 4.50 in static culture (p < 0.0001), while SPPV (TK-) OMP25 achieved 7.08 log10 TCID50/mL versus 4.33 (p < 0.001). These findings confirm the reliability, reproducibility, and scalability of this bioreactor-based approach, demonstrating clear advantages over conventional cultivation methods. Overall, the study highlights the high potential of the BelloStage™-3000 system with BioNOC II® macrocarriers for the industrial production of recombinant capripoxvirus-based vaccines against brucellosis and for the broader development of other recombinant viral vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BioreactorsCapripoxvirusAntigens, BacterialBrucellaBrucella VaccineBrucellosisAnimalsVero CellsChlorocebus aethiopsHumans

Stichwörter der Autor:innen

Vero cell linebioreactorbrucellosiscapripoxvirusmacrocarrierrecombinant vectorserum-free culture medium

Substanzen

Antigens, BacterialBrucella Vaccine

Autor:innen und Institutionen

  • Research Institute for Biological Safety Problems, National Holding "QazBioPharm", Gvardeiskiy 080409, Kazakhstan.

ORCID-Profile: Zhanna Sametova, Olga Chervyakova, Sholpan Turyskeldi, Alina Kurmasheva, Ruslan Abitayev, Abdurakhman Ussembay, Zhanat Kondibayeva, Dariya Toktyrova, Dana Mazbayeva, Yerbol Bulatov

Förderung

  • Ministry of Health of the Republic of Kazakhstan

Zitieren

APA

Amanova, Z., Sametova, Z., Chervyakova, O., Turyskeldi, S., Kurmasheva, A., Abitayev, R., Ussembay, A., Kondibayeva, Z., Toktyrova, D., Mazbayeva, D., & Bulatov, Y. (2025). BelloStage™-3000 Bioreactor Versus Conventional Cultivation of Recombinant Capripoxvirus Expressing Brucella Antigens in Vero Cells: A Step Towards the Development of a New Human Brucellosis Vaccine. Cells, 14(20), 1631. https://doi.org/10.3390/cells14201631

Vancouver

Amanova Z, Sametova Z, Chervyakova O, Turyskeldi S, Kurmasheva A, Abitayev R, et al. BelloStage™-3000 Bioreactor Versus Conventional Cultivation of Recombinant Capripoxvirus Expressing Brucella Antigens in Vero Cells: A Step Towards the Development of a New Human Brucellosis Vaccine. Cells. 2025;14(20):1631. doi:10.3390/cells14201631

BibTeX
@article{Amanova2025,
  author = {Amanova, Zhanat and Sametova, Zhanna and Chervyakova, Olga and Turyskeldi, Sholpan and Kurmasheva, Alina and Abitayev, Ruslan and Ussembay, Abdurakhman and Kondibayeva, Zhanat and Toktyrova, Dariya and Mazbayeva, Dana and Bulatov, Yerbol},
  title = {BelloStage™-3000 Bioreactor Versus Conventional Cultivation of Recombinant Capripoxvirus Expressing Brucella Antigens in Vero Cells: A Step Towards the Development of a New Human Brucellosis Vaccine},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {20},
  pages = {1631},
  doi = {10.3390/cells14201631}
}
Kostenlos starten →